CD4-IgG2 formulations
    1.
    发明申请
    CD4-IgG2 formulations 审中-公开
    CD4-IgG2制剂

    公开(公告)号:US20050142139A1

    公开(公告)日:2005-06-30

    申请号:US10804802

    申请日:2004-03-19

    摘要: This invention provides formulations of the anti-HIV therapeutic, CD4-IgG2, that contain higher concentrations of the therapeutic than were previously prepared, are stable, compatible with lyophilization, and safe to administer. These formulations are suitable for intravenous, subcutaneous and intramuscular delivery, the latter two routes being potentially useful for facilitating self-administration by HIV-infected individuals. This invention is also directed to methods of making the CD4-IgG2 formulations described in the disclosure, and methods of using the formulations to inhibit or prevent infect CD4+ cells from becoming infected with HIV, and to treat subjects having CD4+ cells infected with HIV.

    摘要翻译: 本发明提供了抗HIV治疗剂CD4-IgG2的制剂,其含有比先前制备的更高浓度的治疗剂,其是稳定的,与冻干相容并且安全施用。 这些制剂适用于静脉内,皮下和肌内递送,后两种途径可能有助于促进HIV感染个体的自我施用。 本发明还涉及制备本公开中描述的CD4-IgG2制剂的方法,以及使用制剂抑制或预防感染CD4 +细胞感染HIV的方法,以及治疗感染HIV的CD4 +细胞的受试者的方法。